Bio-Vascular - 500 Beiträge pro Seite

[Hobie]

Hi, an alle!!!
Nach stundenlangem Stöbern im Netz und einem Fachgespräch mit einem Arzt ist mir die Bio-Vascular-Aktie ins Auge gefallen. Mir fehlte nähmlich noch eine Bio-Aktie in meinem Depot. Obwohl es sich hierbei - strenggenommen - um eine Medtech Aktie handelt, war ich doch sehr überzeugt von den finanziellen Daten und deren medizinischen kow-how.
(wollte hier nicht alles ins Board posten was man sich auch selber im Netz ansehen kann: www.nasdaq.com - Kürzel BVAS
über das know-how fragt einfach einen Arzt eures Vertrauens oder, wenn ihr ein wenig mehr Englisch könnt als ich: www.biovascular.com)
Die Firma stellt alles mögliche für den Bereich Arterienverkalkung, Bypass, Überwachung des Ganzen, u.s.w...(bin halt kein Arzt) her. Das Vertriebsnetz ist Weltweit durch Filialen ausgebaut - also eher westliche Länder, aber zum Teil auch Asien.
Was will uns dieser Beitrag sagen??? - Ich möchte damit zur Disskusion anregen und vieleicht hat ja der ein oder andere auch schon Erfahrungen mit diesen Wert.

Gruß Hobie!!!

[Hobie]

Ok, scheint so als interessiere sich keiner für diese Aktie. Vielleicht hätte ich als Überschrift irgend etwas wie: Super Biotech-rakete, die 1000% Chance, Morgen gehts los oder etwas ähnliches schreiben müssen.
Naja, hab ich halt nicht getan und trotzdem meine 89% heute gemacht.
Vielleicht hat ja doch jemand Interesse über diese Aktie zu diskutieren, ich freue mich über jeden Beitrag.

Gruß Hobie!!!

[stilli]

Bin sehr interessiert Hobie. Kannst du mir mehr Informationen über diese Aktie geben, wie z.B. Kurs, WKN usw.
Gruß Stilli

[Hobie]

Hab dir gerade ne Nachricht gesendet, weiß aber nicht ob sie angekommen ist. Wenn nicht, melde dich.

Gruß Hobie!!!

[stilli]

Hi Hobie,
habe leider noch nichts von dir bekommen.
Was macht denn der heiße Bio-Tip ?

Gruß stilli

[Hobie]

Hi stilli,
schau einfach mal bei dem threat:" 100 % in2 Tagen und das ist erst der Anfang " vorbei. Gib als Suchbegriff einfach das Wort Vascular ein. Dort wird das Thema ausführlich diskutiert.


Gruß Hobie!!!

[stan5.]

hi


scheiße was ist da heute los -14% was für gründe gibts oder nur gewinnmitnahmen
da scheine ich wieder mal minus zu machen wer baut mich auf

[mr.lukoil]

Hi Stan,
keine Sorge, nach dem starken Kursanstieg ist die Konsolidierung normal. Bodenbildung duerfte bald erfolgen. Ebenso, wie Biotech insgesamt allmaehlich einen Boden finden duerfte.

GErade Bio-vascular ist fundamental richtig guenstig. Schau Dir mal auf der Nasdaq-Seite bvas fundamental an. Oder ueber Onvista.

Also, in ruhe auf zukuenftige kraeftige Kursgewinne warten.
Gruss

Mr.lukoil

[Hobie]

Hi,
nach einer kräftigen Kurskorrektur (an der Nasdaq -30% für Biotechwerte) habe ich den heutigen Tag genutzt und kräftig nachgekauft. Ich hoffe, daß das die richtige Entscheidung war, denn Bodenbildung dürfte jetzt stattgefunden haben. Ich gehe mit positiven Erwartungen in den morgigen Tag.


Gruß Hobie!!!

[mr.lukoil]

Moin Hobie,

denke, dass Du eine gute Entscheidung getroffen hast. Die Umsaetze in Usa waren gestern schon wieder anziehend. Auch duerften wir wieder steigende Kurse sehen, nachdem sich der Kurs nun nach unten hin gesetzt hat.
Fundamental ist bio-vascular klar unterbewertet. Bin leider nicht liquide, konnte daher nicht bei dieser GElegenheit zugreifen.

In Erwartung schon heute zulegender Kurse.

lukoil

[stan5.]

hi

wolln wir hoffen das ihr recht habt bin zu 8.97 rein habe jetzt schon kräftig miese hoffe geht jetzt wieder hoch
GO BVAS GO


Bezahlt werden fürs surfen wenn ihr wissen wollt wies geht
http://www.planet-interkom.de/stephan.holstein/INTERNET.htm

[mr.lukoil]

Hey stan,

hab selbst bei 7 usd nochmal nachgekauft. Das Problem bei bio-vascular koennte neben dem schnell hochgelaufenen Kurs auch das "bio" im Namen gewesen sein. Da bio-vascular mit Genentschluesselung nun einmal gar nichts zu tun hat, ist die Aktie halt zu Unrecht in diesen Strudel gezogen worden.

Charttechnisch wird jetzt halt der Boden fuer spaetere Kursgewinne gebaut. Wir sind solide ueber den trendlinien. In einigen Wochen/Monaten werden wir uns alle aergern nicht noch mehr gekauft zu haben.

Also stan, schoen dass Du auch noch dabei bist.

lukoil

ps: weisst du, ob der Kardiologen-Kongress noch laeuft?

[Hobie]

Hey mr.lukoil,
ich habe selber vor kurzem einen Bericht mit dem Kardiologenkongress hier reingepostet (nur erwähnt, nicht den Inhalt) . Ich kann ihn aber leider nicht mehr entdecken - verdammt, wo hatte ich das nur gefunden??? Aus meinen Erinnerungen meine ich, daß er noch stattfinden soll, ich bin aber nicht sicher.
Kann jemand eventuell helfen???



Gruß Hobie!!!

[stan5.]

hi

finde auch nichts zum kongress
in amerika ja leicht gestiegen hoffe kommt jetzt noch wieder irgendwie phantasie rein positive analsten oder gute nachrichten
mit guter hoffnung in die nächste woche

[mr.lukoil]

Moooin,

heute geht es ja gleich zu Beginn ueber die 6 Usd. Wurde auch Zeit. Damit hat der Kurs genau am kurzfristigen Aufwärtstrend gedreht und diesen damit bestaetigt.

Schoenes Ding!

Also, eine angenehme Boersenwoche wuenscht

lukoil

[stan5.]

hi

das sieht ja heute wieder mal scheiße aus jetzt habe ich was 50% miese das kotzt mich jetzt voll an wer kann mir mut machen oder soll ich verkaufen



Bezahlt werden fürs surfen wenn ihr wissen wollt wies geht
http://www.planet-interkom.de/stephan.holstein/INTERNET.htm

[Hobie]

Hi,
diese News habe ich von cnbc.com kopiert. Mein Englisch ist aber so schlecht, daß ich damit nichts anfangen kann. Vielleicht ist jemand von euch in Enlisch besser gewappnet als ich und könnte zu dieser News mal ein kurzes Statement posten oder ähnliches.

(Edgar Online via COMTEX)


Company Name: VITAL IMAGES INC
(SYMBOL:VTAL)

MANAGEMENT`S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Overview

Vital Images develops, markets and supports medical visualization and analysis software for use primarily in clinical diagnosis, surgical planning and medical screening. The Company`s software applies proprietary computer graphics and image processing technologies to a wide variety of data supplied by computed tomography ("CT") scanners, magnetic resonance ("MR") imaging devices and ultrasound scanning equipment. Vital Images` products allow clinicians to create both two- and three-dimensional views of human anatomy and to non-invasively navigate within these images to better visualize and understand internal structures and pathologies. The Company believes that its high-speed visualization technology and customized protocols cost-effectively bring 3D visualization and analysis into the routine, day-to-day practice of medicine. The Company, which operates in a single business segment, markets its products to healthcare providers and to manufacturers of diagnostic imaging systems through a direct sales force in the United States and independent distributors in international markets.

On October 28, 1996, the Board of Directors of Bio-Vascular, Inc. ("Bio-Vascular"), the former parent company of Vital Images, approved a plan to spin off and establish Vital Images as an independent, publicly-owned company. On May 12, 1997 (the "Distribution Date"), Bio-Vascular distributed all of the shares of Vital Images to the shareholders of Bio-Vascular (the "Distribution"), and on that date Vital Images began operating as an independent public company. All Bio-Vascular shareholders of record as of May 5, 1997 received one share of Vital Images common stock for each two shares of Bio-Vascular stock held on that date, and cash in lieu of fractional shares. As a result of Bio-Vascular`s spin-off of Vital Images, Vital Images` financial statements and notes thereto report the business of Vital Images as an independent company. Vital Images is currently traded on the OTC Bulletin Board under the symbol VTAL.

In anticipation of the Distribution, Bio-Vascular assigned to Vital Images, $10,000,000 in cash, cash equivalents and marketable securities, effective November 1, 1996. Subsequently, Bio-Vascular`s Board of Directors agreed to make such additional contributions as were necessary to bring cash, cash equivalents and marketable securities to a combined total of $10,000,000 effective as of the Distribution Date. On the Distribution Date, Bio-Vascular contributed to Vital Images an additional $1,845,000 in cash equivalents in order to increase Vital Images` cash, cash equivalents and marketable securities balance to $10, 000,000. Additionally, Bio-Vascular made capital contributions to Vital Images of approximately $3,200,000 representing net advances of cash over the period beginning May 24, 1994, the date on which Vital Images was acquired by Bio-Vascular, and ending May 11, 1997, the last date on which Vital Images was a part of Bio-Vascular.

Revenue

Total revenue increased 46% to $6,623,000 in 1999 compared with $4,527,000 in 1998. Total revenue in 1998 increased 272% from total revenue of $1,218,000 in 1997. These increases were primarily the result of volume increases in shipments of Vitrea(R), the Company`s flagship medical visualization and analysis software. Software and hardware revenue from the Vitrea platform totaled $5,143,000, or 78% of total revenue in 1999, compared with $3,234,000, or 71% of total revenue in 1998, and $404,000, or 33% of total revenue in 1997. Vitrea revenue increased 59% in 1999 compared with 1998 and 700% in 1998 compared with 1997. Vitrea was first released for sale to customers in October 1997. In addition, there were increases in maintenance and service revenue related to Vitrea sales in 1999 as compared with 1998 and from 1998 compared with 1997. Royalties received from the Company`s license agreement with Paradigm Geophysical Corporation ("Paradigm") decreased in 1999 as compared to 1998 but increased in 1998 as compared with 1997. Revenue received under the license agreement with Paradigm was $462,000, $618,000 and $313,000 in 1999, 1998 and 1997, respectively. License fee revenue and maintenance revenue from VoxelView(R) software, the Company`s product for the research market, was flat in 1999 as compared to 1998 and decreased in 1998 as compared to 1997.

Gross Margin

The gross margin percentage increased to 77% in 1999 from 73% in 1998 and 75% in 1997, primarily as a result of increasing the price of the Company`s Vitrea system. The Vitrea system, consisting of Vitrea software and third-party hardware and peripherals, is designed to offer end users an integrated visualization and analysis system. The Company receives only a nominal discount in purchasing the third-party hardware and peripheral components of the Vitrea system, and the Company`s gross margin on the resale of these system components approximates its discount. The Company anticipates that as hardware revenue related to the sale of Vitrea software continues to account for a significant proportion of the Company`s total revenue, the overall gross margin percentage will approximate the results of 1999.

Sales and Marketing

Sales and marketing expenses were $3,886,000, or 59% of total revenue, $2,955,000, or 65% of total revenue, and $2,167,000, or 178% of total revenue, for 1999, 1998 and 1997, respectively. The increase from 1998 to 1999 was primarily due to increased compensation costs as a result of additional personnel and sales commissions. There were also increases in travel expenses as well as advertising and promotion expenses related to selling and promoting the Vitrea product. Depreciation expense also increased in 1999 as compared with 1998, primarily due to equipment purchases used for the additional personnel and equipment for tradeshows. The increase from 1997 to 1998 was primarily due to increased compensation costs as a result of increased sales commissions and additional personnel and increased travel expenses related to selling and promoting the Vitrea product The Company expects sales and marketing costs to increase in future periods primarily as a result of the cost of additional sales personnel.

Research and Development

Research and development expenses were up 39% to $2,525,000, or 38% of total revenue, in 1999 from $1,815,000, or 40% of total revenue, in 1998. The increase was primarily due to a decrease in reimbursement of $285,000 of engineering costs pursuant to a software development contract with ATL Ultrasound, Inc. ("ATL") and an increase in compensation and recruiting costs due to the hiring of additional personnel. There was also an increase in depreciation expense primarily the result of equipment purchases to support the additional personnel as well as to support the development of Vitrea2 for Windows NT(TM). Research and development expenses were $2,255,000, or 185% of total revenue, in 1997. The decrease in 1998 from the 1997 level was primarily due to reimbursement of $285,000 of engineering costs pursuant to the development contract with ATL, fewer software engineers and a decrease in travel expenses. The Company anticipates that research and development expenses will increase in future periods as additional releases of Vitrea software are developed.

General and Administrative

General and administrative expenses were $1,971,000, or 30% of total revenue, $1,999,000, or 44% of total revenue, and $1,703,000, or 140% of total revenue, in 1999, 1998, and 1997, respectively. The decrease from 1998 to 1999 was primarily due to the absence of costs in 1999 related to the resignation of the Company`s former Chief Executive Officer and the decrease of expenses related to the closing of the Company`s Iowa facility, primarily due to negotiating an early termination of the lease for that facility. These decreases were partially offset by increases in shareholder communications and compensation costs. The increase from 1997 to 1998 was due primarily to a charge of $180,000 in connection with the resignation of the Company`s former Chief Executive Officer and expenses of $100,000 related to the planned closing of the Company`s Iowa facility. In December 1998, the Company made a decision to consolidate its operations at its headquarters in Minnesota and close its facility in Iowa. In addition, compensation expense increased as a result of increased staffing and compensation costs for employees hired in 1997 that were present for all of 1998. Incremental costs associated with being an independent public company, including professional fees and shareholder

reporting, also contributed to the increase. These increases were partially offset by a decrease of $441,000 related to stock-based compensation costs in 1997. The Company believes that general and administrative costs will increase in future periods primarily due to increased compensation expense for employees hired in 1999 that will be present for all of 2000 as well as additional costs related to the Company`s new facility.

Results of Operations

The increasing revenues from Vitrea shipments net of the increased expenses attributable to the development of the Company`s infrastructure and the development and promotion of the Vitrea product, resulted in an operating loss of $3,303,000 for 1999 compared with an operating loss of $3,467,000 for 1998 and an operating loss of $5,211, 000 for 1997.

Interest Income

There was $91,000 of interest income for 1999, compared with $264,000 in 1998 and $443,000 in 1997. The decreases in interest income from 1997 to 1998 and from 1998 to 1999 were due to a lower balance of cash, cash equivalents and marketable securities throughout the year as a result of the use of cash to fund the Company`s operations.

Income Taxes

The income tax provisions for 1999, 1998 and 1997 consist solely of certain state minimum fees. A valuation allowance has been established to completely reserve for the deferred tax assets of the Company. As a wholly-owned subsidiary of Bio-Vascular through May 11, 1997, the Company did not file separate federal income tax returns, but rather was included in the federal income tax returns filed by Bio-Vascular. For purposes of the Company`s financial statements prior to the Distribution, the Company`s allocated income tax provisions were based on the "separate return" method.

Liquidity and Capital Resources

As of December 31, 1999, the Company had $5,333,000 in cash and cash equivalents. The Company`s working capital was $5,409,000 and the Company had no material borrowings. The Company has entered into a collateralized line of credit agreement with a bank for $950,000. Borrowings under the agreement are limited to the lower of $950,000 or the Company`s borrowing base, which consists of a specified percentage of certain accounts receivable. The Company is also required to maintain a cash and cash equivalents balance of at least $1,000,000 at the lending bank. As of December 31, 1999, the Company has two outstanding letters of credit, totaling $350,000, collateralized by the line of credit and its available borrowings under the agreement were $600,000.

Cash used in operations increased to $3,064,000 for 1999 from $2,342, 000 in 1998. For 1997, $4,075,000 was used in operations. Cash flows were used primarily to fund operating losses in each of the years 1999, 1998 and 1997, which were partially offset by non-cash expenses for depreciation and amortization and the provision for uncollectible accounts receivable in 1999, 1998 and 1997 and stock-based compensation in 1999 and 1997. Increases in accounts receivable decreased cash flows and increases in current liabilities increased cash flows in each of the years 1999, 1998 and 1997. Changes in deferred revenue resulted in increased cash flows in 1999 and 1998 and in decreased cash flows in 1997.

The increases in current liabilities in 1999, 1998 and 1997 were due primarily to increases in accounts payable and accrued payroll and other liabilities. The increases in accounts receivable and accounts payable were due primarily to volume increases in Vitrea sales and costs related thereto, respectively. The increase in accrued payroll and other liabilities in 1999 was primarily due to increases in accrued vacation, royalties and commissions, offset by a decrease in accrued bonuses. The increases in accrued payroll and other liabilities in

1998 and 1997 were due primarily to increases in bonuses, commissions and accrued vacation pay related to increases in employee headcount.

Net investing activities provided $1,474,000 and $3,555,000 of cash in 1999 and 1998, respectively, primarily due to the conversion of marketable securities into cash. In 1997, the Company used $3,776,000 in investing activities primarily due to the investment of cash in marketable securities. The Company added property and equipment of $512, 000, $423,000 and $796,000 in 1999, 1998 and 1997, respectively, primarily for computer equipment to accommodate the increases in employee headcount in 1999, 1998 and 1997 and for telecommunications equipment to accommodate the Company`s move into new facilities in 1997.

Cash provided by financing activities totaled $5,171,000, $91,000 and $1,818,000 in 1999, 1998 and 1997, respectively. A private placement of the Company`s common stock and warrants completed by the Company in December 1999 was primarily responsible for the cash provided by financing activities in 1999. Net cash investments made by Bio-Vascular of $1,798,000 accounted for nearly all of the cash from financing activities in 1997. During 1999, 1998 and 1997, net cash of $426,000, $91,000 and $20,000, respectively, was provided by proceeds from the Company`s stock option plans.

The Company has never paid or declared any cash dividend and does not intend to pay dividends in the near future. The Company has commitments for approximately $500,000 of capital expenditures related to the Company`s new office facilities. See Note 6 to the financial statements, "Lease Commitments," for additional commitments and contingencies. The Company expects to use cash in the near term as it continues to develop the infrastructure to support its business and develop the market for its products.

If the Company`s operations progress as anticipated, of which there can be no assurance, management believes that its cash, and cash equivalents and borrowings available under the credit agreement should be sufficient to satisfy its cash requirements for at least the next twelve months. The timing of the Company`s future capital requirements, however, will depend on a number of factors, including the ability and willingness of physicians to use three-dimensional visualization and analysis software in clinical diagnosis, surgical planning, patient screening and other diagnosis and treatment protocols; the ability of the Company to successfully market its products; the ability of the Company to differentiate its volume rendering software from competing products employing surface rendering or other technologies; the ability of the Company to build an effective sales and distribution channel; the impact of competition in the medical visualization business; and the ability of the Company to enhance existing products and develop new products on a timely basis. To the extent that the Company`s operations do not progress as anticipated, additional capital may be required sooner. There can be no assurance that any required additional capital will be available on acceptable terms or at all, and the failure to obtain any such capital would have a material adverse effect on the Company`s business.

Year 2000

Many computer programs and embedded computer chips were unable to distinguish between the year 1900 and the year 2000. Therefore, some computer hardware and software needed to be modified prior to the year 2000 in order to remain functional. This is commonly known as the year 2000 ("Y2K") issue.

The Company has a formal program in place with an assigned year 2000 project team to ensure that its critical areas will operate normally at the turn of the century and beyond. Throughout 1999, the year 2000 project team determined areas where contingency planning was needed. The planning efforts included, but were not limited to, identification and mitigation of potential serious business interruptions and establishing crisis response processes to address unexpected problems.

Through the date of this filing, the Company has not experienced any significant Y2K issues. The Company will continue to monitor its Y2K status during the coming year and will devote the necessary resources to resolve all significant Y2K issues in a timely manner.

The costs incurred by the Company in addressing its Y2K readiness issues were primarily non-incremental compensation costs and were not material to the Company`s operating results. The Company currently estimates that the total additional costs for addressing any Y2K readiness will not be material to the Company`s operating results. These costs are being expensed as they are incurred.

The Company`s statements regarding its year 2000 readiness are forward-looking statements and are, therefore, subject to change as a result of known and unknown factors. The Company`s cost estimates could be influenced by the Company`s ability to successfully identify all year 2000 issues, the nature and amount of remediation required, the availability and cost of trained personnel in this area and the year 2000 success that key third parties and customers attain. While these and other unforeseen factors could have a material adverse impact on the Company`s financial position, results of operations or liquidity in future periods due to possible business disruptions caused by a lack of third party year 2000 readiness, management believes that it has implemented an effective year 2000 compliance program that will minimize the possible negative consequences to the Company.

The Year 2000 readiness disclosure statement set forth above is a "Year 2000 Readiness Disclosure" under the federal Year 2000 Information and Readiness Disclosure Act.

Foreign Currency Transactions

Substantially all of the Company`s foreign transactions are negotiated, invoiced and paid in U.S. dollars.

Inflation

Management believes inflation has not had a material effect on the Company`s operations or on its financial condition.

Recent Accounting Pronouncements

In June 1998, The FASB issued SFAS No. 133, "Accounting for Derivative Instruments and Hedging Activities." The new statement establishes accounting and reporting standards for derivative instruments, including certain derivative instruments embedded in other contracts, (collectively referred to as derivatives) and for hedging activities. SFAS No. 133, as amended by SFAS No. 137, is effective for the Company beginning January 1, 2001. The Company does not expect SFAS No. 133 to materially affect its financial position or results of operations.

In January 1999, the AICPA issued SOP 98-9, "Modification of SOP 97-2, Software Revenue Recognition, With Respect to Certain Transactions," which will retain the limitations of SOP 97-2 on what constitutes vendor-specific objective evidence of fair value. SOP 98-9 will be effective for the Company for transactions entered into beginning January 1, 2000. The Company believes that its current revenue recognition policies and practices are consistent with the provisions of the new guidance.

Market Risk

The Company is exposed to market risk related to changes in the fair value of its financial instruments due to changes in interest rates. As of December 31, 1999, the Company did not own any financial instruments.

Forward-Looking Statements

This Annual Report on Form 10-K contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and information that are based on management`s beliefs as well as on assumptions made by, and upon information currently available to, management. When used in this Annual Report on Form 10-K, the words "expect," "anticipate," "intend," "plan," "believe, " "seek," and "estimate," or similar expressions are intended to identify such forward-looking statements. However, this Annual Report on Form 10-K also contains other forward-looking statements. Forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions, including, but not limited to, the following factors, which could cause the Company`s future results and shareholder values to differ materially from those expressed in any forward-looking statements made by or on behalf of the Company: the dependence on market growth of the industry in which the Company operates; the extent to which the Company`s products gain market acceptance; the need for and availability of additional capital; the potential for litigation regarding patent and other intellectual property rights; the introduction of competitive products by others; dependence on major customers; fluctuations in quarterly results; the progress of product development; the availability of third party reimbursement; and the receipt and timing of regulatory approvals and other factors detailed from time to time in the Company`s filings with the Securities and Exchange Commission, including those set forth under the heading "Important Factors" included in Item 1 of this Annual Report on Form 10-K.

Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

The Company`s financial statements, supplemental schedule and Report of Independent Accountants thereon, all of which are included in this Annual Report on Form 10-K, are listed in Item 14 (a) (1) of this Form 10-K.

Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.


(c) 1995-1999 Cybernet Data Systems, Inc. All Rights Reserved.


Received by Edgar Online: Mar. 21, 2000


CIK Code: 0000912888
SEC Accession Number: 0001045969-00-000202

Gruß Hobie!!!

[mr.lukoil]

Moin Stan, moin Hobie!

Stan: Hatte selbst gehofft, schon bei 5.75 die Trendwende zu sehen. Leider sind wir nun noch immer im unteren Bereich. Allerdings waren wir heute lange Zeit bei 5,5 usd. Erstaunlicherweise sieht es immer so aus, dass gegen Handelsende nochmal der Kurs nach unten gedrueckt wird. Finde ich auffaellig.
Natuerlich ist bvas auch markteng. Der Kurs ist dementsprechend volatil.
Ich bleibe jedenfalls dabei. Denke, dass die Aktie mit einer MK von derzeit 45 mio usd. geradezu geschenkt ist. Glaub, das Kurs/umsatz-verhaeltnis liegt bei eins. Natuerlich muss man bei solch einem wert ein wenig Geduld mitbringen.

Hobie: glaub das ist nicht wirklich relevant. Diese dort genannte Gesellschaft ist ein spin-off (Ausgliederung) von bvas. NAch der Ausgliederung wurden die shares - wie in usa ueblich - an die Aktionaere von bvas ausgegeben. Der Rest ist ueber das y2k problem, allgemeine Zukunftsrisiken etc........ Hatte dann irgendwann keine Lust mehr zu lesen.

Jedenfallsgut, dass Du die Augen aufhaeltst. Koennte ja auch mal ein richtiger Knaller bei sein.
Uebrigens: Bist Du Segler? Nur wg. Deines Namens. Komme von der Kueste, daher diese Frage.

Also, ich denke mit Geduld werden wir schon noch unsere soliden Gewinne einfahren.

Gruss

Lukoil

ps.: Stan: Habe einem Kumpel von mir von bvas erzaehlt. Der wird von der DB-Anlage-management betreut. Sein Berater hat sich schliesslich auch bvas gekauft.
Hoffe, dass das nicht Du bist. Nichts fuer ungut.

[Hobie]

Moin mr.lukoil,
erst mal danke für dein Posting. Was die Aktie betrifft, seh ich es genau wie du, ich denke, daß dort noch erhebliches Potential drin ist. Witzig finde ich die Sache mit dem DB-Anlageberater, ich denke, daß das ein kleines Fünkchen Hoffnung für stan5 ist.
Ach ja, segeln tu ich übrigens auch und zwar Hobiecat.


Gruß Hobie!!!

[stan5.]

hi

ja ist ein bißchen hoffnung mal sehen was die amis heute machen

[Hobie]

Hi stan5,
versprich mir bitte eins, wenn die Aktie irgendwann mal richtig abgeht, dann laß uns zusammen mit mr.lukoil nach Zuffenhausen fahren. Bis dahin müssen wir halt durchhalten.


CU (irgendwann) in Zuffenhausen
Gruß Hobie!!!

[stan5.]

ok machen wir
doch wo ist bloß ist zuffenhausen

[Hobie]

Hi Stan5,
Zuffenhausen ist glaube ich in der Nähe von Stuttgard (oh scheiße, ich weiß nicht mal wie das geschrieben wird). Auf jeden Fall wird dort Porsche gebaut. Aber bis dahin ist es noch ein weiter Weg. Ich habe mich an der Nasdaq für Realtimekurse freischalten lassen, der Kurs war eben bei 4.50$ bei sehr geringen Umsätzen. Hoffen wir das Beste, ich bin nähmlich auch schon 10% im Minus. Wird Zeit, daß mal ne schöne News rüberkommt.


Gruß Hobie!!!

[Hobie]

Hier ist die Hammernews auf die wir alle gewartet!!!
Ok,Ok, war nur ein Scherz. Aber vieleicht interessiert sich ja jemand dafür. Warten wir also auf eine wirkliche Hammernews!!!


Gruß Hobie!!!


Bio-Vascular, Inc., Names Fariborz Boorboor Vice President and Chief Operating Officer of Jerneen Subsidiary

ST. PAUL, Minn., March 23 /PRNewswire/ -- Bio-Vascular, Inc. (Nasdaq: BVAS), announced today that Fariborz BoorBoor has been promoted to vice president and chief operating officer of Jerneen, the company`s wholly owned subsidiary. He will report to M. Karen Gilles, Bio-Vascular president and chief executive officer. Previously, BoorBoor served as director of operations at Jerneen.

"Fariborz has broad technical and management experience, as well as a commitment to customer and project priorities," said Gilles. "His ability to lead a team will contribute significantly to the success of Jerneen and Bio-Vascular."

In September 1998, BoorBoor joined Jerneen with more than 20 years of production management experience. Previously, BoorBoor served as quality assurance manager at Plastech Corporation in Rush City, Minn., and as division services manager at Phillips Plastics Corporation in Chippewa Falls, Wis. BoorBoor holds a bachelor`s degree in chemistry and business administration from the University of Wisconsin at Eau Claire.

Bio-Vascular, Inc., is an innovative medical products company that operates through two segments. The company`s Branded Surgical Products segment develops, manufactures and markets proprietary and patented specialty medical products for use in thoracic, cardiac, neuro, vascular and ophthalmic surgery. The company`s Medical Device Components segment, operating through its wholly owned Jerneen subsidiary, is a value-added original equipment manufacturer of micro-precision wire-based component products, including precision coils, stylets and guidewire components and subassemblies used in the medical industry.


/CONTACT: Connie L. Magnuson, CFO of Bio-Vascular, Inc., 651-603-3700, or Nancy A. Johnson of Padilla Speer Beardsley Inc., 612-871-8877, for Bio-Vascular, Inc./

[Hobie]

Hi stan5 und mr.lukoil,
endlich gehts wieder ein Stück bergauf. Heute an der Nasdaq mit 5.31 $ eröffnet. Das sind ca +11%

Gruß Hobie!!!

[Hobie]

Geil, jetzt schon 5.50 $ das Handelsvolumen ist jetzt schon bei 70 tsd, soviel wie an den letzten beiden Tagen zusammen.

Gruß Hobie!!!

[stan5.]

hi

endlich gehts wieder hoch akt mit puls 20% an der nasdaq

Go BVAS GO

[Hobie]

Stan5 und mr.lukoil,
haltet euch fest, bvas waren gerade bei 6.88 $ das sind fast +50%.
Das Handelsvolumen liegt bei knapp 500000 und ich habe jetzt auch den Grund für den heutigen Kursanstieg gefunden:

Study Presented to The Society for Clinical Vascular Surgery Shows Advantages Of Bio-Vascular`s Vascu-Guard(R) Patch

ST. PAUL, Minn., March 27 /PRNewswire/ -- Study results presented at the recent Society for Clinical Vascular Surgery meeting showed that the use of Bio-Vascular`s (Nasdaq: BVAS) Vascu-Guard(R), a bovine pericardial surgical patch, in endarterectomy procedures resulted in significantly less bleeding in comparison to a Dacron(R) patch. An endarterectomy is performed to clear the carotid artery of plaque to prevent stroke. An estimated 130,000 carotid endarterectomy procedures are performed annually in the United States. Stroke is one of the leading causes of death in the world.

Brian J. Marien, M.D., et. al., of Boston University concluded that the blood loss was statistically significantly less when Vascu-Guard was used as the patch material. In the hospital environment, less time spent controlling bleeding at the surgical site typically translates into lower hospitalization costs.

"This is yet another study which demonstrates clinical superiority of Bio-Vascular`s tissue-based surgical products," said M. Karen Gilles, Bio-Vascular president and chief executive officer.

A previously announced study presented in September at the International Society of Cardiovascular Surgery showed that use of Vascu-Guard for patching carotid endarterectomies resulted in clinical outcomes as good as those obtained using the saphenous vein, considered by surgeons to be the "gold standard." The saphenous vein is the patient`s own vein, removed from their leg at the time of surgery.

Bio-Vascular, Inc., is an innovative medical products company that operates through two segments. The company`s Branded Surgical Products segment develops, manufactures and markets proprietary and patented specialty medical products for use in thoracic, cardiac, neuro, vascular and ophthalmic surgery. The company`s Medical Device Components segment, operating through its wholly owned Jerneen subsidiary, is a value-added original equipment manufacturer of micro-precision wire-based component products, including precision coils, stylets and guidewire components and subassemblies used in the medical industry.



Gruß Hobie!!!

[Hobie]

Moin,
und weiter geht´s, Nasdaqeröffnung heute mit 6.25 $. Was ich nicht versteh, warum die in Deutschland mit 5.70 EUR gehandelt werden.


Gruß Hobie!!!

[mr.lukoil]

Moin Hobie,

keine Ahnung. Jedenfalls ist kein Handel zustande gekommen. Wahrscheinlich hat der makler diesen Kurs gestellt, weil er irgendeine Abzockerorder vorliegen hatte.

Sieht ja bis auf bvas (derzeit unveraendert);, grauenvoll an der nasdaq aus.

Bis die Tage

lukoil

[stan5.]

hi

sah ja gestern wieder schrecklich aus aber bei ragingbull wird jetzt heftig über bvas eerzählt die rechnen da bis ende april von kurse von 12$ wäre ja nicht schlecht oder

SIND WIR DIE EINZIGEN DIE BIO_VASCULAR HABEN

cu schönes wochenende

GO BVAS GO

[Hobie]

Hi stan5,
war die ganze Zeit am Segeln und hab heute erst wieder reingeschaut.
Ich denke auch, daß wir die einzigen sind die bvas haben, deshalb finde ich diesen threat voll lustig. Warten wir einfach mal ab, bis sich die Baisse ausgebaisst hat, dann werden wir auch wieder richtig Gewinne einfahren.
Interessant finde ich, daß bvas nun auch im ragingbull behandelt wird. Ich muß zugeben, daß ich dort so manchen meiner Zockerwerte gefunden habe (techniklone, nastech, starnet ...). Obwohl ich nach wie vor von bvas überzeugt bin, d.h., ich halte es nicht für einen Zock, sondern für einen soliden Medtechwert.


Ok stan5 und mr.lukoil
Viel Glück in der Baisse
Gruß Hobie!!!

[stan5.]

hi ich bin noch investiert tut sich ja langsam wieder was akt. in den usa bei 5$ mache jetzt endlich wieder was gut go bvas go und das bei dem markt warum der anstieg weiß wer was??

[stan5.]

es scheint das ich wirlcih der einzigste bin der dei hat?

[mr.lukoil]

Hi Stan, bin natuerlich auch noch dabei. Wird halt ein bißchen langfristiger als anfaenglich gedacht. Mich wuerde allerdings interessieren, ob Hobie auch noch drin ist. Denke im Fruehjahr stellen sich die heutigen Kurse als Geschenk dar. Mal schauen..

so long
Lukoil

[mr.lukoil]

Hallo,

schade, dass sich niemand mehr meldet. Dabei gab es doch gerade erst am Freitag eine Kaufempfehlung.

Der Boden bei 4 Usd hat gehalten und die Aktie scheint den Aufwärtstrend wieder aufgenommen zu haben. Die 5 usd koennten wir in Kuerze ja wieder in Angriff nehmen. Dann gibt es nicht mehr viel Widerstand.

Sehr schoen auch, dass bvas die Gewinnzone erreicht hat (quelle: WWW.NASDAQ.com) Noch mehr gute Nachrichten und es gibt bald mal wieder einen schoenen Schub.

Also, ich hoffe, daß nach andere meine wieder aufkeimende Freude teilen.

so long.

lukoil

[mr.lukoil]

Hallo,

scheint fast so, als sei ich der einzige, der hier noch diese Aktie hält. Wenn auch mit verringerter Position.
Immerhin inzwischen steuerfrei im plus.

Ist noch jemand an board? Wie seht Ihr die weitere Entwicklung?

Könnte das heute eine Nachkaufgelegenheit sein?

Gruß

lukoil

[mr.lukoil]

Hier mal ein paar Infos:
Bio-Vascular Reports Another Record-Setting Quarter

Momentum in Net Revenue and Earnings Growth Continues; Revenue and Earnings
Exceed Expectations

ST. PAUL, Minn., May 16 /PRNewswire/ -- Bio-Vascular, Inc. (Nasdaq: BVAS), today reported consolidated results for its second quarter ended April 30, 2001.

Consolidated net revenue increased 33 percent to $7,110,000 in the second quarter from $5,343,000 in the same period of fiscal 2000. Operating income rose to $689,000 from a loss of $108,000 in the year-ago quarter. The company generated net income of $447,000, or five cents per diluted share, compared to a net loss of $38,000, or zero cents per share, in the second fiscal quarter of the previous year.

For the first half of fiscal 2001, consolidated net revenue increased 37 percent to $13,371,000 from $9,725,000 for the first half of fiscal 2000. The company produced operating income of $1,189,000 compared to an operating loss of $396,000 for the same period last year. Consolidated net income rose to $780,000, or nine cents per diluted share, compared to a net loss of $167,000, or two cents per share in the year-ago period. Net cash flow provided by operations during the six months ended April 30, 2001, was $1,151,000 compared to a $400,000 use of cash in operations during the same period of fiscal 2000.

"Our excitement runs high for all segments of our business as each makes strong contributions to top- and bottom-line growth," said Karen Gilles Larson, Bio-Vascular president and chief executive officer. "Second-quarter revenue of $7.1 million is 14 percent higher than the preceding quarter and 12 percent higher than the third quarter of fiscal 2000, the previous all-time quarterly revenue high. Operating income for the six-month period was $1.2 million while last year at this time we had an operating loss of $396,000.

"In addition to our revenue and earnings growth, our positive net cash flow is strengthening our already strong financial position," commented Larson. "This quarter marks the fourth consecutive fiscal quarter of positive cash flow. Cash has increased by $1.5 million in the twelve-month period ended April 30, 2001 to a current balance of $6.0 million. We are managing our business to achieve significant, profitable growth and generate the necessary free cash flow to finance the $1.1 million invested over the past twelve months in capital expenditures in support of that growth. The generation of free cash flow also opens the door to more opportunities for the company." Branded Medical Devices

Net revenue from BVI`s branded medical devices increased 14 percent to $3,765,000 for the second quarter of fiscal 2001 from $3,301,000 in the year-ago quarter and generated operating income of $312,000 compared to operating income of $162,000 in the same quarter last fiscal year.

Larson continued, "The momentum of U.S. Peri-Strips(R) sales is continuing, with a 56 percent increase over the second quarter of last fiscal year and a 58 percent increase in comparison to the first six months of last fiscal year. In addition, sales of other branded products are generally showing steady growth. We believe we are still in the very early stages of establishing a market for the use of Peri-Strips in gastric bypass procedures."

In February 2000, Bio-Vascular received FDA 510(k) marketing clearance for and commenced sale of Peri-Strips for use in gastric bypass and gastric banding procedures, surgical treatments for morbid obesity. Peri-Strips are used to provide integrity to the staple line in these procedures, helping to ensure good clinical outcomes and reduce the costs associated with staple-line complications.

Controlling morbid obesity can mitigate costly related conditions, including heart disease and diabetes. Gastric bypass procedures are gaining acceptance rapidly and growing in numbers annually. Forecasts indicate the number of these procedures performed in the United States could grow to 100,000 in 2004, from 45,000 in 1999, creating an estimated $100 million market opportunity. Morbid obesity is not a common condition in the rest of the world.

The company filed a patent application in September 1999 for its next generation remodelable tissue. This advanced material has been named Veritas(TM). In pre-clinical animal studies, Veritas demonstrated greater biocompatibility, lower levels of inflammation and lower levels of fibrosis when compared to two competitive products. The first use of Veritas is as a sling for the surgical treatment of stress urinary incontinence (SUI). A full market launch of this application of Veritas will begin later in the year, following the collection of clinical outcomes sought for marketing advantage.

In the United States, 13 million people, mostly women, suffer from SUI. Sling procedures are the fastest-growing surgical treatment for SUI. The sling application of Veritas has been cleared to market by the U.S. Food and Drug Administration and the company plans to file for the CE Mark later in the year. In Europe, 19 million people are estimated to suffer from SUI. Micro Medical Technologies (MMT)

Net revenues from MMT jumped 64 percent to $3,345,000, compared to $2,042,000 in the year-ago quarter and produced operating income of $377,000 compared to an operating loss of $270,000 in this same period last year. Larson commented, "MMT is on the move, adding people and work shifts to meet the rapidly growing demand generated by its high quality manufacturing and delivery standards. This business has demonstrated its ability to provide top-notch and highly responsive design and engineering services, which are fueling manufacturing growth. We expect the MMT segment of our business will have an annual growth rate in excess of 40 percent this year. With revenue growth rates of 110 percent and 64 percent in the first and second quarters of this fiscal year, respectively, the quarterly growth rates in the final two quarters of the year will logically be smaller rates of growth in order to average the anticipated substantial 40 percent annual growth rate." Research & Development Program

Second quarter consolidated research and development (R&D) expenses were $410,000, compared to $570,000 in the second quarter last fiscal year. The decrease in expenses is the net result of a smaller Ph.D. staff within the branded medical device business, offset by more engineers at MMT and the variability in timing of animal studies. Significant expenses were incurred in the year-ago quarter for the animal studies to evaluate the sling product. Outlook for Fiscal 2001

For the fiscal year ending October 31, 2001, the company expects revenue growth to exceed 20 percent, with an annual revenue growth rate in the mid- to high-teens in the branded medical device segment of its business and more than 40 percent in the MMT segment. Factors that could affect performance include the timing of product introductions, the number of certain surgical procedures performed and the level of orders from MMT`s manufacturing customers.

Bio-Vascular, Inc. is a diversified medical device company engaged in developing, manufacturing and bringing to market products to improve the quality of human life. The company`s businesses encompass branded biomaterial products, along with surgical productivity tools, and licensed and distributed products. Its Micro Medical Technologies (MMT) business custom designs, engineers and manufactures precision micro-wire components that are used primarily in interventional cardiovascular and neurological medical devices. For additional information on Bio-Vascular and its products, visit the company`s Web site at http://www.biovascular.com

Forward-looking statements contained in this press release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The statements can be identified by words such as "should," "may," "will," "expect," "believe," "anticipate," "estimate," "continue," or other similar expressions. Certain important factors that could cause results to differ materially from those anticipated by the forward-looking statements made herein include the timing of product introductions, the number of certain surgical procedures performed and the level of orders from contact manufacturing customers. A full discussion of factors can be found in the company`s Annual Report in Form 10-K for the year ended October 31, 2000.


BIO-VASCULAR, INC.
Consolidated Results of Operations (unaudited)
(In thousands, except per share data)

Three Months Ended Six Months Ended
April 30 April 30
2001 2000 2001 2000

Net revenue $7,110 $5,343 $13,371 $9,725
Cost of revenue 3,554 2,703 6,671 4,728
Gross margin 3,556 2,640 6,700 4,997
Gross margin percentage 50% 49% 50% 51%
Selling, general and
administrative 2,457 2,178 4,717 4,217
Research and development 410 570 794 1,176
Operating income (loss) 689 (108) 1,189 (396)
Other income, net 46 32 94 63
Income (loss) before
provision for
(benefit from)
income taxes 735 (76) 1,283 (333)
Provision for
(benefit from)
income taxes 288 (38) 503 (166)

Net income (loss) $447 $(38) $780 $ (167)

Basic and diluted income
(loss) per share $0.05 $(0.00) $0.09 $(0.02)


Weighted basic shares
outstanding 8,914 8,810 8,908 8,808
Weighted diluted shares
outstanding 9,215 8,810 9,158 8,808


Business Segment Information
(In thousands)
Three Months Ended Six Months Ended
April 30 April 30
2001 2000 2001 2000

Net revenue
Branded Medical
Devices $3,765 $3,301 $ 7,362 $6,414
Micro Medical
Technologies 3,345 2,042 6,009 3,311
Total 7,110 5,343 13,371 9,725

Gross margin
Branded Medical
Devices 2,380 2,190 4,539 4,103
Micro Medical
Technologies 1,176 450 2,161 894
Total 3,556 2,640 6,700 4,997

Gross margin percentage
Branded Medical
Devices 63% 66% 62% 64%
Micro Medical
Technologies 35% 22% 36% 27%
Total 50% 49% 50% 51%

Operating income (loss)
Branded Medical
Devices $312 $162 $597 $97
Micro Medical
Technologies 377 (270) 592 (493)
Total 689 (108) 1,189 (396)


Consolidated Condensed Balance Sheets
As of April 30, 2001 and October 31, 2000

(in thousands, except share and per share data)
April 30, October 31,
2001 2000
(Unaudited)

ASSETS
Current assets:
Cash and cash equivalents $6,000 $5,480
Accounts receivable, net 4,368 3,561
Inventories, net 4,457 3,926
Other 456 765
Total current assets 15,281 13,732


Equipment and leasehold improvements, net 4,979 4,630
Goodwill and other intangible assets, net 5,679 6,024
Deferred income taxes 277 417
Total assets $26,216 $24,803


LIABILITIES AND SHAREHOLDERS` EQUITY
Current liabilities:
Accounts payable and accrued expenses $3,046 $2,495
Current maturities of long-term obligations 227 294
Total current liabilities 3,273 2,789


Capital lease obligations and other
long-term obligations 296 392
Total liabilities 3,569 3,181


Shareholders` equity:
Preferred stock: authorized 5,000,000
shares of $.01 par value; none issued
or outstanding at April 30, 2001 and
October 31, 2000 -- --

Common stock: authorized 20,000,000
shares of $.01 par value; issued and
outstanding, 9,010,982 and 8,975,061
at April 30, 2001 and October 31, 2000,
respectively 90 90
Additional paid-in capital 27,751 27,596
Unearned compensation (197) (287)
Accumulated deficit (4,997) (5,777)
Total shareholders` equity 22,647 21,622
Total liabilities and shareholders` equity $26,216 $24,803


MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X31682444



/CONTACT: Nancy A. Johnson of Padilla Speer Beardsley Inc., 612-871-8877, for Bio-Vascular, Inc., or Connie L. Magnuson, CFO of Bio-Vascular, Inc., 651-603-3700/
Home | About Nasdaq | Feedback | Help & Reference
Equity & Index Options | Site Map, Index, Search

[mr.lukoil]

Seit der vermeintlichen Nachkaufgelegenheit immerhin +20%. In absehbarer Zeit könnten sich wieder die alltime-highs erreichen lassen. Wenn das jetzt mal nicht wieder einbricht.
Scheint nur alles kaum jemanden zu interessieren.

ciao

lukoil

[mr.lukoil]

Bio-Vascular, Inc., Named One of Minnesota`s Best-Performing Small Public Companies by Ventures Magazine

MINNEAPOLIS, June 7 /PRNewswire/ -- Bio-Vascular, Inc., (Nasdaq: BVAS), was named to the list of the 50 Best-Performing Small Public Companies headquartered in Minnesota in the June issue of Ventures Magazine. Bio-Vascular ranked 20th on the list of companies with market capitalizations less than $50 million. The rankings are based on five core criteria: annual stock price change, earnings growth, change in full-time equivalent employee count, revenue growth in dollars, and revenue growth in percent and were measured for the most recent four fiscal quarters ended by March 31, 2001.

"The theme of our 2000 annual report was `No Limit,`" said Karen Gilles Larson, president and chief executive officer. "At Bio-Vascular, we define our future in these terms. Our current growth is a result of our strategy to position ourselves in multiple sizeable markets and our ability to execute that strategy. We are achieving significant, profitable growth while generating the free cash flow to finance our growth initiatives. Our full R&D pipeline creates a continuing stream of potential. We are positioned for an exciting future."

Bio-Vascular, Inc. is a diversified medical device company engaged in developing, manufacturing and bringing to market products to improve the quality of human life. The company`s businesses encompass branded biomaterial products, along with surgical productivity tools, and licensed and distributed products. Its Micro Medical Technologies (MMT) business custom designs, engineers and manufactures precision micro-wire components that are used primarily in interventional cardiovascular and neurological medical devices. For additional information on Bio-Vascular and its products, visit the company`s Web site at http://www.biovascular.com

[mr.lukoil]

Kurs inzwischen über 13 USD. Wäre sicher für viele ein gutes investment gewesen.
gruss lukoil

heissen inzwischen übrigens synovis

[mr.lukoil]

synovis: Inzwischen waren wir bis auf über 23 USD.
Läuft grossartig und scheinbar weiter unbeachtet von der breiten Masse (hier interessiert das ja auch keinen!
jetzt Korrektur auf 19,xx usd. Man wird sehen ob es eine Topbildung ist, oder halt nur eine Korrektur.
Seit Eröffnung des threads jdf. 500 %!